Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330314 · ClinicalTrials.gov registry record · Phase 1
Molar Potency Study of HM12460A in Healthy Subjects
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03330314: Completed Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
NCT03330314 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03330314, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
Primary Outcome
\- Comparison of HM12460A to insulin glargine based on blood glucose profile generated by intravenous infusion
Interventions
- BIOLOGICAL HM12460A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 1 |
What the finished NCT03330314 record still lists
NCT03330314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which HM12460A is the first listed.
NCT03330314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03330314 about?
NCT03330314 is a clinical study titled "Molar Potency Study of HM12460A in Healthy Subjects". This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
What is the current status of trial NCT03330314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-10-24. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT03330314?
The interventions under investigation include: HM12460A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03330314?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03330314's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI